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Summary
Dimethylarginine dimethylaminohydrolase (DDAH) is
involved in the regulation of nitric oxide synthase
(NOS) by metabolizing the free endogenous arginine
derivativesNu-methyl-L-arginine (MMA)andNu,Nu-di-
methyl-L-arginine (ADMA), which are competitive in-
hibitors of NOS.Here, wepresent high-resolution crys-
tal structures of DDAH isoform 1 (DDAH-1) isolated
from bovine brain in complex with different inhibitors,
including S-nitroso-L-homocysteine and Zn2+, a regu-
lator of this mammalian enzyme. The structure of
DDAH-1 consists of apropeller-like fold similar toother
arginine-modifying enzymes and a flexible loop, which
adopts different conformations and acts as a lid at the
entrance of the active site. The orientation and interac-
tion mode of inhibitors in the active site give insight
into the regulation and the molecular mechanism of
the enzyme. The presented structures provide a basis
for the structure-based development of specific
DDAH-1 inhibitors thatmight be useful in the therapeu-
tic treatment of NOS dysfunction-related diseases.
Introduction
Nitric oxide (NO) is an important signaling and effector
molecule involved in pathophysiological and physiolog-
ical processes such as neurotransmission, regulation of
vascular tone, and bacterial defense (Colasanti and
Suzuki, 2000). NO is produced by three homologous
nitric oxide synthases (NOS) converting L-arginine to
L-citrulline: endothelial NOS (eNOS) and neuronal NOS
(nNOS), which are predominantly regulated by cytosolic
Ca2+, which, in turn, modulates protein-protein interac-
tion between calmodulin and NOS (Bredt and Snyder,
1994; Kone et al., 2003), and the inducible NOS (iNOS).
High toxicity, free diffusibility, and potent chemical reac-
tivity of the free radical NO require strict, tight control of
the three isoforms of NOS to enable efficient signaling
and to prevent simultaneous damage to other cellular
components (Rassaf et al., 2004). For example, several
cardiovascular risk factors like hypertension, smoking,
diabetes mellitus, and vascular inflammation are related
to the dysfunction of NOS (Vallance and Leiper, 2004).
It is well established that NO synthesis can be com-
petitively inhibited by the endogenously methylated ar-
ginine derivatives Nu-methyl-L-arginine (monomethy-
*Correspondence: gruetter@bioc.unizh.chlated L-arginine, MMA) and Nu,Nu-dimethyl-L-arginine
(asymmetric dimethylated L-arginine, ADMA). MMA
and ADMA are competitive endogenous inhibitors of
all three isoforms of NOS, while Nu,Nu-dimethyl-L-argi-
nine (symmetric dimethylated L-arginine, SDMA) does
not inhibit NOS (Leiper and Vallance, 1999; Tran et al.,
2003). Methylated arginines appear in proteins that are
modified posttranslationally (Paik and Kim, 1971) or as
free amino acids in various mammalian tissues (Ueno
et al., 1992). The enzyme Nu,Nu-dimethyl-L-arginine di-
methylaminohydrolase (DDAH, EC 3.5.3.18) converts
MMA and ADMA to L-citrulline and mono- or dimethyl-
amine, respectively, thus regulating NOS activity (Mac-
Allister et al., 1996). This enzyme does not degrade the
non-NOS inhibitor SDMA.
Mammalian DDAH exists in two isoforms—DDAH-1,
which colocalizes mainly with nNOS, and DDAH-2,
which is predominantly expressed in tissues containing
eNOS—suggesting an isoform-dependent regulation of
NOS (Tran et al., 2000). Overexpression of DDAH acti-
vates NOS (Dayoub et al., 2003), whereas inhibition of
DDAH leads to accumulation of ADMA, causing de-
creased NOS activity and NO levels (Cooke, 2004). In-
creased levels of MMA and ADMA in plasma and urine
have been implicated in diseases linked with low levels
of NO, such as uremia, chronic heart failure, atheroscle-
rosis, and hyperhomocysteinemia (Tsao and Cooke,
1998). In contrast, in diseases such as septic shock, mi-
graine, inflammation, and neurodegenerative disorders,
excess NOS activity or NO production is involved (Val-
lance and Leiper, 2002). Attenuation of NO production
by inhibiting DDAH might therefore be a valuable ap-
proach to fight these diseases.
Besides the known endogenous DDAH inhibitors
L-citrulline, Zn2+, L-homocysteine, and S-nitroso-L-
homocysteine, only a few designed inhibitors that are
either not selective for DDAH or lack DDAH isoform
specificity are currently known (Rossiter et al., 2005;
Stone et al., 2005; Vallance et al., 2005). Although the
crystal structure of a bacterial DDAH is known (Mur-
ray-Rust et al., 2001), modeling of a mammalian enzyme
structure was deemed difficult because of low sequence
similarity (Rossiter et al., 2005).
Here, we present various high-resolution crystal
structures of the mammalian DDAH-1 from bovine brain,
which include: (1) structures of the unliganded enzyme
in two different crystal forms, (2) structures of the Zn2+
bound enzyme at two different pH values, and (3) struc-
tures of the enzyme in complex with the reaction
product L-citrulline, the inhibitor L-homocysteine, and
the endogenous suicide inhibitor S-nitroso-L-homocys-
teine. Based on the DDAH-1 structure, a high-quality ho-
mology model of the bovine enzyme isoform DDAH-2
could be built that reveals differences in the binding
pocket between both isoforms.
The structures presented here can serve as an ideal
basis for the design of inhibitors that could have a
potential pharmaceutical use in diseases in which over-
production of NO is involved (Vallance and Leiper,
2002).
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902Table 1. X-Ray Data and Refinement Statistics
Zn2+ (pH 9.0) Zn2+ (pH 6.3) Ia IIa Citb Hcyc HcyNOd
Space group P212121 P212121 P21 P21 P21 P21 P21
Wavelength (A˚) 1.0000 0.8550 0.9793 0.9793 1.0001 0.9793 0.8998
Cell dimensions
a (A˚) 44.38 44.40 40.96 42.84 40.7 44.7 40.66
b (A˚) 74.63 76.49 79.61 81.02 80.1 79.4 79.91
c (A˚) 81.40 81.49 44.87 44.68 44.9 70.6 44.89
b (º) 90 90 108.5 100.6 108.08 104.8 108.58
Resolution (A˚) 1.6 2.0 1.7 1.7 1.2 1.8 1.08
Completeness (%)e 98.4 (96.0) 99.2 (96.3) 96.2 (93.3) 99.3 (93.6) 98.0 (94.3) 98.1 (90.7) 98.6 (96.0)
Number of unique reflections 35,849 19,299 28,708 32,693 91,611 48,415 114,012
Multiplicity 7.24 5.08 2.62 3.45 2.98 3.25 3.65
I/s(I)e 10.4 (4.5) 10.8 (4.0) 12.0 (4.8) 16.9 (4.8) 10.8 (2.0) 9.5 (2.2) 15.7 (4.1)
Rsym
e 7.6 (49.7) 6.8 (44.2) 8.7 (29.3) 6.0 (19.8) 7.0 (33.4) 12.6 (37.6) 7.7 (33.9)
Processing program XDS Denzo Denzo Denzo Denzo Denzo Denzo
Resolution range (A˚) 20–1.6 40–2.0 30–1.7 30–1.7 20–1.2 30–1.8 20–1.08
Number of reflections in
working and test set
35,844/1,182 19,241/935 27,225/1,392 31,033/1,622 81,946/2,580 45,805/2,422 112,848/1,126
Rcryst (%) 20.3 22.9 18.8 19.4 12.2 17.6 11.1
Rfree (%) 23.8 25.9 21.9 21.7 16.8 21.2 14.0
Water moleculesf 333 98 336 247 393 (5) 656 482
Rmsd
Bond lengths (A˚) 0.004 0.006 0.004 0.004 0.013g 0.007 0.016g
Bond angles (º) 1.3 1.2 1.4 1.3 0.030g 1.4 0.034g
Mean B value (A˚2) 24.0 29.6 16.6 21.0 15.0 14.0 13.3
a Crystal forms I and II of Zn2+ free DDAH-1.
b–d Complex structures with L-citrulline (Cit), L-homocysteine (Hcy), and S-nitroso-L-homocysteine (HcyNO), respectively.
e Values in parentheses are for the highest-resolution shell.
f Numbers in parentheses indicate the number of half waters.
g Rmsd values in A˚ for the refinements with SHELX.Results
Overall Structure
We determined crystal structures of ligand-free DDAH-1
in two different crystal forms, of DDAH-1 with bound
Zn2+ at pH 6.3 and pH 9.0, and of DDAH-1 in complex
with L-citrulline, L-homocysteine, and S-nitroso-L-ho-
mocysteine at high resolution (between 1.08–2.0 A˚; see
Table 1). The overall fold of the enzyme consists of five
repeats of a bbab motif (Figure 1A) with a root-mean-
square deviation (rmsd) of 0.19–0.50 A˚ for all Ca atoms
between the different structures. The CATH Database
classifies the protein as a five-stranded propeller be-
longing to the homologous superfamily of L-arginine/
glycine amidinotransferase (3.75.10.10) (Orengo et al.,
1997).
As a result of the modular architecture of DDAH-1,
there is a channel in the center of the molecule that is
closed in the middle by a salt bridge between Glu77
and Lys174 that, in turn, forms the bottom of the active
site (Figure 1B). One side of the channel represents a wa-
ter-filled pore delineated by the first b strand of each of
the five propeller blades. The other side of the channel is
the active site cleft whose outermost boundaries are de-
fined by short loop regions and a helical structures. A
flexible loop region formed by amino acids 25–36 closes
the active site upon binding of the substrate (Figures 1A
and 2).
Structure of the Unliganded Enzyme and
Conformational Changes in the Lid Region
Three different conformations for a surface stretch rep-
resenting amino acids 25–36, here referred to as the lidregion, were observed in the various structures (Fig-
ure 2). A closed form was observed in five structures
of the liganded enzyme, in the Zn2+-containing structure
at pH 9.0, and in one unliganded enzyme structure (crys-
tal form I, see Table 1). Crystal packing in crystal form I
containing the unliganded enzyme prevents the lid re-
gion from adopting an open conformation. The open
conformation was observed in crystal form II of the unli-
ganded enzyme. Here, the lid region forms an a helix re-
orienting Leu29 12 A˚ away from the active site and leav-
ing the active site entrance open and accessible for the
substrate to enter and bind. An alternative open confor-
mation was observed in the Zn2+-containing structure at
pH 6.3, indicating high flexibility of the lid region in the
open conformation. The high flexibility of the lid region
is also reflected by high crystallographic B factors: the
average B factor value for amino acids 25–36 is 50 A˚2,
compared to an overall value of 21 A˚2 (Figure 3). The
closed lid conformation allows for the formation of an
additional hydrogen bond between the amino group of
the ligand and the main chain carbonyl of Leu29. This
additional interaction enables the rearrangement from
the a-helical (open) to the loop (closed) conformation
of the lid. In the latter case, the isobutyl side chain of
Leu29 blocks the entrance of the active site (Figure 2).
Structures of Zn2+ Bound to the Active Site
The protein purified from bovine brain contained one
Zn2+ ion with an occupancy of w95% and an apparent
dissociation constant ofw4 nM as previously described
(Knipp et al., 2001). This protein was crystallized at pH
6.3 and pH 9.0. The conformation of the lid loop is differ-
ent in the two structures. In the crystal form grown at pH
Crystal Structure of Mammalian DDAH
903Figure 1. Overall Structure of DDAH-1
(A) Stereoview of the overall structure of
DDAH-1 (ribbon depiction) in complex with
L-citrulline (space filled). The bbab blades of
the propeller are colored green, magenta,
cyan, orange, and blue from the N to the C ter-
minus. The connecting loops and helices be-
tween the blades are colored gray. Residues
25–36 form a lid shown in red. L-citrulline is
shown with carbon atoms in yellow, nitrogen
in blue, and oxygen in red. All figures were
generated with the program PyMOL (DeLano,
2002).
(B) Stereoview of a cross-section through
DDAH-1. The DDAH-1 L-citrulline complex
was used for the surface representation. Wa-
ter molecules were excluded for the calcula-
tion of the surface. Water molecules in the
water channel and in the pore are shown as
red spheres, and L-citrulline is shown as
a stick model. The two residues, Glu77 and
Lys174, shielding the active site from the
water-filled pore are shown in green, and
the lid is shown in red.6.3, the lid region adopts a second open conformation
(Figure 2) that is fixed by water molecules mediating
crystal contacts. At pH 9.0, the lid is in a closed confor-
mation that is induced by a glycine molecule present in
the crystallization buffer acting as a ligand.
The observed distances and angles between zinc and
the coordinating atoms at both pH values are summa-
rized in Tables 2 and 3. In both structures, the Zn2+ is
bound to the enzyme in a distorted tetrahedral environ-
Figure 2. Conformations of the Lid Region
The three different conformations of the lid region of DDAH-1 are
shown. The open conformation (crystal form II), the closed confor-
mation (crystal form I), and the Zn2+ bound structure at pH 6.3 are
shown in blue, red, and green, respectively (Table 1). Residues 24–
37 for all three structures are represented as ribbons, and the side
chain Leu29 is shown as a stick model. The surface is calculated
by using the structure of crystal form II without water molecules.
L-citrulline is shown as a stick model, and the active site cysteine
is marked by a yellow surface. The distance between the Cg atom
of Leu29 in the open and closed conformation is 12 A˚. N and C
mark the N- and C-terminal end of the lid, respectively.ment coordinated by Cys273 and three water molecules.
At pH 6.3, two water molecules are hydrogen bonded to
the side chains of Asp78 and Glu77. The third water mol-
ecule is not stabilized by additional protein ligands
(Figure 4A and Tables 2 and 3).
At pH 9.0, the Zn2+ is still in a tetrahedral environment;
however, the position compared to the structure at pH
6.3 is slightly changed (Figure 4B and Tables 2 and 3).
At pH 9.0, the side chain of His172 is deprotonated and
the salt bridge to Asp126 is weakened, allowing His172
to adopt two different conformations in the same struc-
ture (Figure 4B). The first conformation is equivalent to
Figure 3. Comparison of the Temperature Factors of Crystal Forms I
and II
B factors (A˚2) of each residue were averaged and plotted against the
residue number. Overall B factors of crystal forms I and II were 17
and 21 A˚2, respectively. A mean B value of 50 A˚2 in the open confor-
mation (crystal form II) indicates the high mobility of the lid region. In
the closed conformation (crystal form I), the mean B value is only
18 A˚2 for these residues, indicating that the lid region is more rigid.
Structure
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which are hydrogen bonded to Asp78, Glu77, and
His172, coordinate the Zn2+ ion. In the second conforma-
tion, the imidazole group coordinates the Zn2+ directly:
the distal nitrogen of the side chain is now in the position
as the water ligand observed in the first conformation.
L-Citrulline, L-Homocysteine, and S-Nitroso-L-
Homocysteine Bound to DDAH-1
Crystals of the closed lid conformation were obtained
with L-citrulline, the product of the enzymatic reaction
bound in the active site of DDAH-1 (Figure 5A). Difference
electron density maps revealed clear density in the ac-
tive site for the ligand, although citrulline was not in-
cluded in the first round of model building (Figure 5A).
Its Ca-carboxyl group forms three salt bridges, two with
the guanidino group of Arg144 of DDAH-1, and one with
the guanidino group of Arg97. Two hydrogen bonds be-
tween the Ca-amino group of the ligand and the main
chain carbonyls of Val267 and Leu29 of the enzyme as
well as a salt bridge to the side chain of Asp72 further sta-
bilize L-citrulline in the active site. In addition, side chains
of Asp78 and Glu77 form hydrogen bonds to the ureido
moiety of L-citrulline and position the ligand in the active
site. The hydrophobic moiety (Cb–Cd) is shielded by
Phe75 on one side and Leu171 on the other side. Sg of
Cys273 points away from L-citrulline, indicating a steric
hindrance between the protein and the ligand. The active
site water occupies the same position as it did in the
structure of the bacterial enzyme (Murray-Rust et al.,
2001). It forms a hydrogen bond with the side chain hy-
droxyl group of Ser175 and the proximal nitrogen of the
imidazole ring of His172. The active site water molecule
is linked to a series of three water molecules in a water
channel leading to the surface of the enzyme (Figure
1B). This water channel allows for the replenishment of
water molecules that participate in the hydrolysis of
MMA and ADMA.
L-homocysteine has been identified recently as a risk
factor for cardiovascular diseases (Lentz et al., 2003). A
number of investigations report on elevated levels of
ADMA and a decreased production of NO in hyperho-
Table 2. Distances between Zinc and the Coordinating Atoms
Crystal Structure Zn-S(p)a Zn-N(p)a Zn-O(w)a
pH 6.3b 2.19 — 1.84, 1.92, 2.37
pH 9.0c 2.27 2.38 2.08, 2.03, 1.81
Mean value of
observed distances
(Alberts et al., 1998)
2.21 6 0.13 2.07 6 0.09 2.12 6 0.15
a (p) or (w) indicate protein or water ligands, respectively.
b Coordinate error 6 0.23.
c Coordinate error 6 0.1 A˚ (Cruickshank, 1999).mocysteinemia (Bo¨ger et al., 2000; Selley, 2003; Stu¨hlin-
ger et al., 2003). Recently, homocysteine was reported
to directly inhibit DDAH in vitro. From their data, the au-
thors proposed the formation of a disulfide bridge be-
tween homocysteine and DDAH (Stu¨hlinger et al., 2001).
Our structure in the presence of L-homocysteine
clearly indicates that L-homocysteine binds in the active
site pocket in the same orientation as L-citrulline (Fig-
ure 5B), and that it binds with a closed lid conformation.
However, even in the absence of reducing agents, no
electron density of a formed disulfide bond was found
between the two sulfur atoms. Therefore, our results do
not support the formation of a disulfide bond proposed
by Stu¨hlinger et al. (2001).
Knipp et al. (2005) showed that upon reaction of
DDAH-1 with S-nitroso-L-homocysteine a so far unob-
served covalent product, N-thiosulfoximide (Cys273:
S-NH-S(O):homocysteine), exists in the active site. The
proposed reaction proceeds through a sulfiliminosulfo-
nium ion (Cys273:S-N]S+-homocysteine 4 Cys273:
S+]N-S-homocysteine). Isotope labeling experiments
revealed that the oxygen atom from a water molecule is
incorporated, reacting exclusively with the sulfur atom
of homocysteine (Knipp et al., 2005). In the crystal struc-
ture, N-thiosulfoximide is clearly seen in the difference
Fourier electron density map (Figure 5C). Interestingly,
refinement of the structure revealed two isomers of N-
thiosulfoximide: Cys273:S-NH-S(O):homocysteine and
Cys273:S(O)-NH-S:homocysteine. Since the specific at-
tack of a water molecule on the sulfur atom of homocys-
teine has already been shown (Knipp et al., 2005), the for-
mation of both isomers in the crystal structure is, to our
knowledge, new, indicating a subsequent slow rear-
rangement previously not observed.
N-thiosulfoximide is stabilized by several salt bridges
and hydrogen bonds (Figure 6). Similar to what occurs in
the other DDAH-1 complex structures, Arg144 and
Arg97 stabilize the Ca-carboxyl group via salt bridges,
whereas Leu29, Val267, and Asp72 stabilize the Ca-
amino group. As was already observed in the DDAH-1
L-citrulline complex, the lid region adopts a closed con-
formation. The nitrogen atom ofN-thiosulfoximide forms
a hydrogen bond to Asp78 in both isomers. However,
the hydrogen bond between the thionyl oxygen and
the proximal nitrogen atom of the imidazole group of
His172 is only present in the isomer with the oxygen
atom bound to the homocysteine sulfur atom. On the
other hand, a hydrogen bond to the main chain nitrogen
of Leu270 stabilizes the isomer with the oxygen atom lo-
cated at the Cys273 sulfur atom.
The nitrogen atom of N-thiosulfoximide occupies
a similar position as N3 of L-citrulline, and there is a slight
shift of 0.6 A˚ toward Cys273 due to longer S-N and C-S
bonds and the missing repulsion of the free side chain of
Cys273 as seen in the DDAH-1 L-citrulline complex. AsTable 3. Angles between Zinc and the Coordinating Ligands
Crystal Structure S-Zn-N N-Zn-O S-Zn-O O-Zn-O
pH 6.3 — — 112.0, 107.6, 100.1 102.5, 109.3, 125.0
pH 9.0 126.7 99.6, 105.6 113.9, 114.8, 110.0 114.0, 95.6, 107.3
Mean value of observed
angles (Alberts et al., 1998)
112 6 4 110 6 9 105 6 7 111 6 9
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905Figure 4. Zn2+ Binding Site
(A) 2Fo 2 Fc Fourier map of the Zn
2+ binding
site at pH 6.3. The active site residues
Cys273, His172, Glu77, and Asp78 and resi-
due Asp268 are shown as sticks. The bound
Zn2+ ion is shown in gray, and the bound wa-
ter molecules are shown in red. Metal ion li-
gand interactions are represented as dotted
lines, and their corresponding lengths are in-
dicated in A˚.
(B) 2Fo 2 Fc Fourier map of the Zn
2+ binding
site at pH 9.0. Interactions of the metal ion
in the first and second coordination sphere
are shown. The Zn2+ atom is shown in gray,
and water molecules are shown in red. The
second conformation of His172 and the alter-
nating water molecule are shown in gray and
purple, respectively.structural information on N-thiosulfoximides are not
available in the Cambridge Structural Database (Allen,
2002), bond lengths were compared to similar com-
pounds. Bond lengths of 1.81, 1.62, 1.63, 1.5, and 1.81 A˚
for Cb to Sg, Sg to N, N to Sd, Sd to O, and Sd to Cg
(Cys273:S-NH-S(O):Hcy), respectively, agree well with
modeled data for oxidized methionine (Schuttelkopf
and van Aalten, 2004) and small-molecule X-ray data
for sulfoximines (Cambridge Structural Database [Allen,
2002]). As seen for small molecules, the S-N bond
lengths in the N-thiosulfoximide isomers are shorter
(1.62/1.63 6 0.03 A˚ and 1.59/1.62 6 0.03 A˚ respectively
[Cruickshank, 1999]) than expected for a single bond
S-N (1.7 A˚) indicating partial double bond character. Re-
markably, superposition of the active site residues of the
L-citrulline and N-thiosulfoximide structures only
showed a difference in the newly formed S-N bond of
the N-thiosulfoximide. As the first collection of diffrac-
tion data revealed a partially cleaved N-thiosulfoximide
resulting in several not clearly defined degradation
products in the active site, e.g., cysteine or homocys-
teine derivatives of sulfenic acids (R-S-OH) or sulfinic
acids (R-S(]O)-OH), further data acquisition was per-
formed with lower radiation intensity (data not shown).
Besides the formation of N-thiosulfoximide, an S-ni-
trosylation of Cys83 was also observed. The solvent-ex-
posed Cys83 is located at the lower end of the pore. This
modification may be due to a transnitrosylation reaction
between S-nitroso-L-homocysteine and Cys83 under
the crystallization conditions. The previously reported
S-nitrosylation of Cys221 with DEA/NO, liberating gas-
eous NO, was not observed in our structure (Knipp
et al., 2003). Cys221 is located in the core of the protein
and is accessible to gaseous NO, whereas modifications
by S-nitrosohomocysteine are restricted to solvent-ac-
cessible residues like Cys273 or Cys83.
Comparison to Other Arginine-Modifying Enzymes
The overall fold of DDAH-1 from bovine brain is identical
to the fold of Pseudomonas aeruginosa DDAH (Pa
DDAH; rmsd 1.39 A˚) and to other arginine- or substitutedarginine-modifying enzymes of which crystal structures
have been determined. Peptidylarginine deiminase
(PAD4) (Arita et al., 2004), converting L-arginine to L-cit-
rulline and ammonium; the Arg:Gly amidinotransferase
(AT) (Humm et al., 1997), involved in creatine biosynthe-
sis; and arginine deiminase (ADI) (Das et al., 2004), an
enzyme that uses arginine as an energy source in the ar-
ginine-deiminase pathway, showed rmsd values of 1.9,
1.78, and 1.82 A˚, respectively.
The sequence identity between DDAH-1 andPaDDAH
is low, around 30%. Superposition of the two structures
reveals differences in the length and positions of a heli-
ces. The active site clefts nevertheless are very similar.
Except for Asp126, all amino acids involved in binding
and conversion of the substrate ADMA to L-citrulline
and dimethylamine are identical in both structures. Re-
markably, amino acids 25–36 of DDAH-1 and amino
acids 15–25 of Pa DDAH showed no sequence identity
other than a conserved Leu29 or Leu18 in Pa DDAH,
demonstrating the importance of this amino acid for
the function of the lid (Figure 7).
Superposition of DDAH-1 in complex with L-citrulline
and ADI (crystal form I [Das et al., 2004]) revealed a sim-
ilar positioning of the ureido moiety of L-citrulline near
the active site cysteine. Compared to the covalent inter-
mediate structure of ADI, the ideal position for the car-
bon atom of the substrates to be attacked resides 0.4
6 0.04 A˚ (Cruickshank, 1999) closer to the active site
cysteine. Although the side chain of Cys273 rotates
120º around Cb to overcome the close contact of Sg
with L-citrulline, we ascribe the small shift of the L-citrul-
line molecule to these repulsive interactions.
Lys174 of DDAH-1 is a key determinant for substrate
specificity. The positively charged side chain of Lys174
in DDAH-1 is unable to coordinate the substrate ADMA
or MMA. Instead, Glu77 of DDAH-1 coordinates the un-
methylated nitrogen of the substrate. This enables the
enzyme to accommodate the bulkier substrates MMA
and ADMA. ADI and AT contain an Asp at this position
that coordinates both terminal nitrogens in the guani-
dino moiety of arginine. Furthermore, the pockets that
Structure
906Figure 5. Active Site of DDAH-1 with Bound
Ligand
(A–C) Stereoviews of the active site of DDAH-1
with (A) L-citrulline, (B) L-homocysteine, and
(C) S-nitroso-L-homocysteine are shown.
Difference electron density maps shown in
yellow and contoured at 3s were calculated
by using the model of DDAH-1 without ligand.
The ligand protein interactions are shown as
red lines. Sg of Cys273 and Sd of homocys-
teine are 3.5 A˚ apart (black, [B]).bind the methylamine or dimethylamine moiety of the
substrates in DDAH-1 and Pa DDAH are larger and are
composed of polar and hydrophobic residues, whereas
ADI has a smaller pocket, which is formed only by polar
side chains. Despite the differences mentioned, com-
parison of the structures supports the finding that mem-
bers of the family of guanidino group-modifying en-
zymes share a common catalytic mechanism (Shirai
et al., 2001).
Comparison of the Two Isoforms of DDAH
Analysis of human DDAH mRNA distribution in various
tissues indicates differential expression of both isoforms
in brain regions, in immune cells, and during develop-
ment. Mainly, DDAH-2 was found in immune cells that
express iNOS, suggesting the importance in the control
of MMA and ADMA levels (Tran et al., 2000). The align-
ment of three mammalian DDAH protein sequences isshown in Figure 7. Percentage scoring values of 92%
for DDAH-1 and 95% for DDAH-2 protein sequences
show high identity within an isoform, whereas the score
drops tow50% when sequences between the two iso-
forms are compared. Nevertheless, residues directly in-
volved in the catalytic mechanism (Cys273, Asp126,
and His172 in DDAH-1 and Cys276, Asp125, and
His171 in DDAH-2) are conserved throughout the com-
pared mammalian DDAH sequences. Variations in amino
acid sequences are found in substrate binding residues
and in the lid region. The lid region in DDAH-2 is highly
conserved and negatively charged through Glu27,
whereas proteins belonging to the DDAH-1 isoform con-
tain a less conserved, positively charged lid region. The
amino acids that are directly involved in substrate bind-
ing are conserved within each isoform among different
species, but they are altered between isoforms 1 and 2.
These different direct interactions include hydrophobic
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907Figure 6. N-Thiosulfoximide in the Active Site
of DDAH-1
Stereoview of the binding of N-thiosulfoxi-
mide to DDAH-1. The water molecules in-
volved in binding of the inhibitor are shown
as red spheres. The connecting hydrogen
bonds and salt bridges are colored as red
dots, and their corresponding lengths are in-
dicated in A˚. Nitrogen atoms are blue, oxygen
atoms are red, and sulfur atoms are yellow.contacts, e.g., Phe75 to Leu74 in DDAH-2, as well as po-
lar interaction, e.g., Glu77 to Gly76 or Arg144 to Trp143.
The modeled active site of DDAH-2 superimposed on the
experimentally determined active site of DDAH-1 illus-
trates these differences (Figure 8). The exchange of
Ala28 for Glu27 in DDAH-2 might compensate for the
Asp72-to-Leu71 mutation because both acidic side
chains are ideally positioned to form salt bridges to the
Ca-amino group of the substrate, whereas the distance
of the side chain of Trp143 is too far away to coordinate
the Ca-carboxyl of the substrate. Overall, three salt
bridges between the enzyme and the ligand are altered
between the two isoforms. Although there are differ-ences in the binding of the substrate to the enzyme, the
overall architecture of DDAH-2 is similar to the one ob-
served in the DDAH-1 structures.
Discussion
Despite the low sequence identity between the mamma-
lian DDAH-1 and the bacterial Pa DDAH (Murray-Rust
et al., 2001), the overall fold is identical and the active
sites are very similar. However, significant differences
exist that are important for a better understanding of
the enzyme mechanism and critical for structure-based
drug design. Our study of the mammalian enzymeFigure 7. Alignment of DDAH Sequences
The sequence alignment of mammalian DDAH sequences and the bacterial PaDDAH sequence (top, based on bacterial and mammalian enzyme
structures). The line above the sequences indicates identical, asterisk; positively charged, plus sign; negatively charged, minus sign; differently
charged, ‘‘0’’; tiny polar, colon; tiny nonpolar, open diamond; aliphatic, pound sign; and aromatic residues, closed diamond in mammalian DDAH
sequences. The green bars indicate residues involved in binding of L-citrulline, red residues indicate residues involved in conversion of the sub-
strate, blue indicates amino acids in the lid region, and yellow indicates residues with a large deviation in Ca position between DDAH-1 and Pa
DDAH. ClustalW (Thompson et al., 1997) was used for the mammalian sequence alignments, whereas Pa DDAH was structurally aligned to
DDAH-1 (crystal form I).
Structure
908Figure 8. Comparison ofDDAH-1andDDAH-2
Stereoview of the superimposed active sites
of the experimentally determined structure
of DDAH-1 (green) and the modeled DDAH-2
(gray). L-citrulline is shown in yellow. The
main chain, except for glycines and carbonyl
atoms involved in binding, is hidden. The
model was created with the program
Modeller 8v1 (Marti-Renom et al., 2000).shows that the lid adopts a helical structure and an open
conformation when no ligand or only Zn2+ is bound, and
that it closes the active site when L-citrulline, L-homo-
cysteine, or S-nitroso-L-homocysteine are bound. The
isobutyl side chain of Leu29 in the lid blocks the en-
trance to the active site completely, buries the ligands,
and thereby stabilizes the enzyme ligand complex. After
hydrolysis of MMA or ADMA, both products, L-citrulline
and methylamine or dimethylamine, are released from
the reaction center. L-citrulline leaves the enzyme
upon the opening of the closing lid through the active
site, whereas, for both amines, two possibilities exist.
First they could leave in a manner similar to L-citrul-
line—through the active site entrance. Alternatively,
they could leave through the pore opened by small
movements of the side chains of Glu77 and Lys174.
As isolated, the enzyme contains one tightly bound
zinc ion (Kd of w4 nM) that reversibly inhibits its enzy-
matic activity. Knipp et al. (2001) reported that the coor-
dination sphere of this Zn2+ ion contains two sulfur
atoms and two lighter atoms (N or O). Coordination of
Zn2+ by Sg of Cys221 and Cys273 was proposed since
Zn2+ protected both sulfurs from S-nitrosylation by gas-
eous NO (Knipp et al., 2003). The presented crystal
structures of the Zn2+ ion containing DDAH-1 demon-
strate that besides Cys273 no additional sulfur ligand
is found in the proximity of the metal ion. All presented
structures adopt the same overall fold, and, besides
the loop region, no flexibility of the protein was found;
therefore, it can be ruled out that Cys221, which is lo-
cated 12 A˚ away, participates in the binding of the metal
ion. The second sulfur ligand, observed by EXAFS, must
therefore be an exogenous ligand, introduced during
purification of the enzyme. The other ligands of the
Zn2+ ion observed in the structures are water molecules
and His172. Since the second conformation of His172 is
only present in the structure at pH 9, we suggest that this
conformation rather reflects a high pKa value of this his-
tidine that is similar to the pKa values of histidines in the
active sites of other cysteine proteases (Lakhdar-Ghazal
et al., 2002). Water molecules positioned by the protein
as in the active site at pH 6.3 or pH 9.0 mediate tight
binding equal to that of a direct protein ligand; therefore,
we assume that the metal ion is coordinated by one pro-
tein ligand (Cys273) and three water molecules, which
are fixed to the protein by a hydrogen bonding network.Reduction of NO production is desirable in diseases
such as septic shock, pain, arthritis, or asthma (Vallance
and Leiper, 2002). In these cases, a specific inhibition of
NOS isoforms is sought. So far, the clinical use of NOS
inhibitors has been limited due to the absence of spec-
ificity or toxicity. Although new promising compounds
inhibiting iNOS have already been developed, a com-
plete inhibition of NOS isoforms may be unwanted (Al-
derton et al., 2005). Inhibition of DDAH isoforms offers
an alternative approach to reduce NO levels in a tis-
sue-specific manner. At present, three different classes
of DDAH inhibitors, including pentalfluorophenyl sulfo-
nates (Vallance et al., 2005), 2-chloroacetamidine (Stone
et al., 2005), and the class of improved DDAH inhibitors,
derived from the weak reversible inhibitor S-2-amino-
4(3-methylguanidino)butanoic acid (4124W) (Rossiter
et al., 2005), are reported in the literature. Although,
not selective or isoform specific, in combination with
the structures presented here, they can serve as a basis
for the development of selective/specific inhibitors.
Inhibitors having a distinct selectivity for DDAH should
(1) form hydrogen bonds to the side chains of Asp72,
Glu77, Asp78, Arg144, and Arg97 and to the main chain
carbonyls of Leu29 and Val267, (2) recognize the posi-
tively charged side chain of Lys174, and (3) form hydro-
gen bonds to His172 and the main chain carbonyl of
Leu270. These features should provide sufficient affinity
to bind to DDAH and selectivity for DDAH compared to
binding to ADI or AT. When comparing the active sites
of the structure of DDAH-1 with the modeled active
site of DDAH-2, seven side chains forming the binding
site are different. An inhibitor, which interacts with the
indole ring of Trp143 (Arg144 in DDAH-1), should show
preferential binding to DDAH-2. A hydrogen bond to
Thr127 in DDAH-2 (Gly128 in DDAH-1) would further en-
hance the specificity toward DDAH-2. In contrast, inhib-
itors that form a hydrogen bond to the side chain of
Glu77 in DDAH-1 (Gly76 in DDAH-2) should bind prefer-
entially to DDAH-1. In addition, the different polarity and
size of the side chains of Leu71 (DDAH-2) and Asp72
(DDAH-1) could be exploited to increase the specificity
toward one of the isoforms. These differences could al-
low for the design of selective and specific inhibitors for
each isoenzyme. Such inhibitors would be of high inter-
est for DDAH research and treatment of diseases linked
to NO overproduction.
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Protein Purification
Protein purification and activity measurements were performed as
described, with minor modifications (Knipp et al., 2001). All purifica-
tion steps, except the second ion exchange chromatography, were
performed at 4ºC. Tissue homogenization of bovine brains, ammo-
nium sulfate precipitation, and the subsequent hydrophobic interac-
tion chromatography were performed as previously described
(Knipp et al., 2001).
Anion Exchange Chromatography
The conductivity of the protein sample was adjusted with H2O to
%15 mU21cm21 and was then applied to a Fractogel EMD TMAE
(s) column (2.6 3 15 cm, Merck) equilibrated with 20 mM triethanol-
amine/HCl (pH 7.8). The protein was eluted with a linear salt gradient
from 0 to 200 mM KCl, and the active fractions were pooled.
Size Exclusion Chromatography
The protein solution was concentrated by ultrafiltration (Amicon) by
using a polyethersulfone membrane (Biomax, Milipore) with a molec-
ular weight cutoff of 5 kDa. The final protein sample (10 ml) was ap-
plied to a HiLoad 26/60 Superdex 75 column (Pharmacia) equili-
brated with 10 mM triethanolamine/HCl, 150 mM KCl (pH 7.4). The
active fractions were combined.
Anion Exchange Chromatography
The conductivity of the protein sample was adjusted with H2O to
%15 mU21cm21 and was then applied to a Mono Q HR 5/5 column
(Pharmacia) equilibrated with 10 mM triethanolamine/HCl, 10% (v/v)
glycerol (pH 7.4). The protein was eluted with a linear salt gradient
from 0 to 200 mM KCl, and the active fractions were pooled.
Protein homogeneity was routinely analyzed by SDS-PAGE and
mass spectrometry. Metal-to-protein ratios were determined by
measuring the Zn2+ concentration by flame atomic absorption spec-
troscopy (SpectrAA-110, Varian, Inc.), and that of the protein was
measured spectrophotometrically (3280 = 14,420 M
21 cm21) (Bogu-
mil et al., 1998).
The fully Zn2+-loaded protein was prepared through protein dialy-
sis against Zn2+-containing buffer (Knipp et al., 2003).
Preparation of Zn2+-free DDAH-1
To remove Zn2+ from native DDAH-1, 200 ml protein sample (w50
mM) was dialyzed at 4ºC against 50 ml metal-free 100 mM imidaz-
ole/HCl and 10 mM DTT (pH 6.5). The outer solution was steadily
bubbled with argon. The dialysis buffer was changed four times
(every 2 hr), and dialysis was completed overnight. To remove imid-
azole and DTT, the protein was dialyzed against two changes of 50
ml metal-free 10 mM MES/NaOH, 150 mM KCl, 2 mM TCEP, 5 mM
EDTA (pH 6.5) (Knipp et al., 2001).
Preparation of L-Homocysteine and S-Nitroso-L-Homocysteine
L-homocysteine was prepared from L-homocysteine thiolacto-
ne$HCl as described by Duerre and Miller (1966) in a nitrogen atmo-
sphere. The yield (96%) was estimated through quantification of
thiols (Grasetti and Murray, 1967).
S-nitroso-L-homocysteine was always freshly prepared under an-
aerobic conditions by using the protocol of Feelisch and Stamler
(1996). Briefly, 150 ml 200 mM L-homocysteine was mixed with an
equal volume of 200 mM NaNO2. After completion of the reaction,
HEPES/EDTA was added to a final concentration of 50 mM
HEPES/5 mM EDTA, and the pH was adjusted to 7.3. The concentra-
tion of the S-nitroso-L-homocysteine formed was determined pho-
tometrically with the molar extinction coefficients reported by Feel-
isch and Stamler (1996).
Crystallization
The protein was concentrated to 2–3 mg/ml in protein storage buffer
(10 mM Tris/HCl, 150 mM KCl, 10% [v/v] glycerol [pH 7.4]). Crystal-
lization was done at 4ºC by using the sitting drop vapor diffusion
method combining 3 ml protein solution and 3 ml reservoir solution.
The final conditions were 100 mM MES/NaOH, 20%–40% PEG
8000 (pH 6.3) or 0.05 M glycine/HCl, 28% PEG 3350 (pH 9.0) for
the Zn2+-containing proteins and 100 mM citric acid/NaOH, 20%–
40% PEG 8000, 2 mM TCEP (pH 6.3) for the free form of the enzyme
and the cocrystallization experiments. For complex structures, 50
mM L-citrulline, 5 mM L-homocysteine, or 0.5 mM S-nitroso-L-ho-
mocysteine were added to the protein solution prior to crystalliza-tion. The crystals were stabilized by adding 20%–25% ethylenegly-
col to the crystallization buffer and were flash frozen in liquid
propane.
Data Collection, Structure Determination, and Refinement
All data was collected on X06SA at the Swiss Light Source (SLS), Vil-
lingen, Switzerland, by using a MarCCD 165 mm detector. Images
were processed with XDS (Kabsch, 1993) or Denzo (Otwinoswki
and Minor, 1997). Structure determination was solved by molecular
replacement by using AMoRe (Navaza, 1994) and a poly-serine
model of the DDAH structure from P. aeruginosa (PDB code:
1H70). Model building and refinement were done with O (Jones
et al., 1991) and CNS (Brunger et al., 1998); the atomic resolution
structures (complexes with L-citrulline or S-nitroso-L-homocys-
teine) were further refined with SHELX (Sheldrick and Schneider,
1997). Cocrystallized small molecules were not included in the
search models, but clear positive density with contour levels higher
than 3s in difference Fourier maps appeared in the first round of
refinement. The position of the Zn2+ was confirmed by anomalous
difference Fourier maps contoured at 8s in Fourier maps. The re-
straints for L-citrulline, the N-thiosulfoximide derivative of cysteine,
L-homocysteine, and S-nitrosocysteine were calculated on the
ProDRG server (Schuttelkopf and van Aalten, 2004) and compared
with the small-molecule database (Allen, 2002). Data collection
and refinement statistics are shown in Table 1. Models were vali-
dated by using SFcheck and PROcheck (CCP4, 1994).
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